Business Wire

VERACODE

28.7.2022 08:52:11 CEST | Business Wire | Press release

Share
Veracode Expands Platform Capabilities in its EU-Resident Platform

Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform in Europe. Companies can now secure their software across the entire software development lifecycle (SDLC) with the added capabilities of dynamic analysis and API scanning, complementing Veracode’s static analysis, software composition analysis and manual penetration testing tools. The Veracode European Region , a cloud-based instance, allows customer data to stay resident in the EU to meet policy requirements for cloud computing.

Demand for a SaaS-based software security solution that supports data residency has never been greater. With a 20x increase * in security scanning cadence over the past decade, organisations are now testing apps for flaws more thoroughly than ever. Many are shifting further left and combining static, dynamic, and software composition analysis to gain a comprehensive view of risk and compliance to policies.

Veracode’s EMEA Chief Technology Officer, John Smith, said, “The European market has a growing need to consolidate and automate application security, while meeting stringent data residency requirements. The options for achieving this at scale are limited and complex: on-premise solutions require a large, upfront investment and frequent upgrades, while other SaaS platforms are often a pared-down version of existing on-premise products. Veracode’s cloud-native platform helps customers keep costs down and increase efficiencies by integrating multiple software security tools into one easy-to-use solution that also monitors policy compliance.”

Based in Frankfurt, Germany, the Veracode European Region is a cloud-based instance that offers customers in EMEA a broad suite of solutions as part of its unified Continuous Software Security Platform, which bridges the gap between security and development teams. Dynamic analysis and API scanning are the latest capabilities to be made available in the market. The integrated platform is unique since it gives customers a “single pane of glass” view of security posture across their entire SDLC.

Seamlessly embedded into the environments where developers work, Veracode creates a frictionless experience for developers to code securely without compromising speed of delivery. This is paramount to help businesses keep pace with accelerating deployment times, as well as to provide a comprehensive view of risk, remediation guidance, peer benchmarking, and rich analytics throughout the development pipeline.

Powered by nearly two decades of aggregate data, the cloud-native platform continually finetunes itself to improve accuracy, yielding impressively low false-positive rates. It also streamlines workflows by running daily updates of the vulnerability database, so customers are immediately apprised of any potential threats.

A customer of Veracode, a European commerce body, said, “The privacy and protection of our customers is our highest priority, so we need to be confident in our software security programme. Veracode gives us this assurance with a fully SaaS platform that is resident in the EU. Initially, we needed an automated dynamic analysis product that could crawl our applications at scale but wanted to avoid the pain of amassing several disparate tools over time. With Veracode, we are safe in the knowledge that we can leverage multiple solutions in one place as we continue to shift security further left.”

Find out more about Veracode’s European Region here .

*Veracode State of Software Security Report v12, February 2022

About Veracode

Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.

Learn more at www.veracode.com , on the Veracode blog and on Twitter .

Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

Link:

ClickThru

Social Media:

https://www.facebook.com/VeracodeInc/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release

Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye